germans trias i pujol - Fundació Institut d'Investigació en Ciències de ...
germans trias i pujol - Fundació Institut d'Investigació en Ciències de ...
germans trias i pujol - Fundació Institut d'Investigació en Ciències de ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
3,554<br />
<strong>Fundació</strong> <strong>Institut</strong> <strong>d'Investigació</strong><br />
<strong>en</strong> <strong>Ciències</strong> <strong>de</strong> la Salut<br />
Germans Trias i Pujol<br />
Lopez‐Pousa A, Losa R, Martin J, Maurel J, Fra J, Sierra M, Casado A, <strong>de</strong>l Muro JG, Poveda A, Balana C, Martinez‐Trufero J, Esteban<br />
E, Buesa JM.<br />
Phase I/II trial of doxorubicin and fixed dose‐rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study.<br />
BRIT J CANCER 2006; 94(12):1797‐1802.<br />
4,459<br />
Plas<strong>en</strong>cia C, Martinez‐Balibrea E, Martinez‐Cardus A, Quinn DI, Abad A, Neamati N.<br />
Expression analysis of g<strong>en</strong>es involved in oxaliplatin response and <strong>de</strong>velopm<strong>en</strong>t of oxaliplatin‐resistant HT29 colon cancer cells.<br />
INT J ONCOL 2006; 29(1):225‐235.<br />
2,556<br />
Raz DJ, He B, Rosell R, Jablons DM.<br />
Curr<strong>en</strong>t concepts in bronchioloalveolar carcinoma biology.<br />
CLIN CANCER RES 2006; 12(12):3698‐3704.<br />
6,177<br />
Raz DJ, He B, Rosell R, Jablons DM.<br />
Bronchioloalveolar carcinoma: a review.<br />
Clin Lung Cancer 2006;7:313‐22<br />
Rosell R, Cecere F, Cognetti F, Cuello M, Sanchez JM, Taron M, Reguart N, Jablons D.<br />
Future directions in the second‐line treatm<strong>en</strong>t of non‐small cell lung cancer.<br />
SEMIN ONCOL 2006; 33(1):S45‐S51.<br />
3,064<br />
Rosell R, Cecere F, Santarpia M, Reguart N, Taron M.<br />
Predicting the outcome of chemotherapy for lung cancer.<br />
CURR OPIN PHARMACOL 2006; 6(4):323‐331.<br />
6,916<br />
Rosell R, Cuello M, Cecere F, Santarpia M, Reguart N, Felip E, Taron M.<br />
Treatm<strong>en</strong>t of non‐small‐cell lung cancer and pharmacog<strong>en</strong>omics: where we are and where we are going.<br />
CURR OPIN ONCOL 2006; 18(2):135‐143.<br />
3,571<br />
Rosell R, Cuello M, Cecere F, Santarpia M, Reguart N, Felip E, Taron M.<br />
Usefulness of predictive tests for cancer treatm<strong>en</strong>t.<br />
BULL CANCER 2006 ;93 :E101‐8<br />
Rosell R, Taron M, Galvez M, Pastor MC, Queralt C, Pradas A, Motia M, Perez M, Reguart N, Moran T, Sanchez JM, Amador ML,<br />
As<strong>en</strong>sio JL, Massuti B, Paz‐Ares L on behalf of the Spanish Lung Cancer Group.<br />
Determinación <strong>de</strong> las mutaciones <strong>de</strong>l receptor <strong>de</strong>l factor <strong>de</strong> crecimi<strong>en</strong>to epidérmico <strong>en</strong> paci<strong>en</strong>tes con cáncer <strong>de</strong> pulmón no<br />
microcítico tratados únicam<strong>en</strong>te con erlotinib.<br />
FMC: Oncologia 2006;1:140‐9<br />
Rosell R, Taron M, Reguart N, Isla D, Moran T.<br />
Epi<strong>de</strong>rmal growth factor receptor activation: how exon 19 and 21 mutations changed our un<strong>de</strong>rstanding of the pathway.<br />
CLIN CANCER RES 2006 Dec 15;12(24):7222‐31.<br />
6,177<br />
Rosell R.<br />
Circumv<strong>en</strong>ting resistance to EGFR‐specific cancer therapy.<br />
Adv Lung Cancer 2006;7:3‐7<br />
Rosell, R.<br />
Optimizing chemotherapy in non‐small cell lung cancer.<br />
Am J Cancer 2006;5:211‐2<br />
Pàgina 161/177
Change language